| scholarly article | Q13442814 |
| P2093 | author name string | Jing Zhou | |
| Christopher Aiken | |||
| Chin Ho Chen | |||
| P2860 | cites work | The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid | Q24793247 |
| Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation | Q28360742 | ||
| Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction | Q29615257 | ||
| Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis | Q35845204 | ||
| Betulinic acid derivatives as HIV-1 antivirals | Q36009015 | ||
| The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. | Q36187060 | ||
| Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation | Q36944553 | ||
| PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing | Q37089562 | ||
| Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. | Q39685850 | ||
| Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. | Q39880513 | ||
| Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles | Q40357793 | ||
| Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. | Q40894533 | ||
| Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives | Q41066416 | ||
| Proteolytic processing and particle maturation | Q41100821 | ||
| 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro | Q42424208 | ||
| The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA. | Q44003068 | ||
| p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents | Q45761377 | ||
| P433 | issue | 24 | |
| P304 | page(s) | 12095-12101 | |
| P577 | publication date | 2006-10-11 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag | |
| P478 | volume | 80 |
| Q39917695 | A single amino acid substitution in a segment of the CA protein within Gag that has similarity to human immunodeficiency virus type 1 blocks infectivity of a human endogenous retrovirus K provirus in the human genome |
| Q42546287 | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle |
| Q27324263 | Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors |
| Q37287731 | Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity |
| Q24614498 | HIV type 1 Gag as a target for antiviral therapy |
| Q35761626 | HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors |
| Q38366763 | HIV-1 gag: an emerging target for antiretroviral therapy. |
| Q34529834 | HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice |
| Q33351623 | High-throughput screening-based identification of paramyxovirus inhibitors |
| Q38032330 | Human Immunodeficiency Virus Gag and protease: partners in resistance |
| Q35992805 | Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. |
| Q28829072 | Identification of potent maturation inhibitors against HIV-1 clade C |
| Q37192174 | Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457) |
| Q24617174 | Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers |
| Q37901613 | New approaches for antiviral targeting of HIV assembly |
| Q33624690 | Novel approaches to inhibiting HIV-1 replication. |
| Q26771739 | Pharmacological intervention of HIV-1 maturation |
| Q33864444 | Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat |
| Q21092230 | Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice |
| Q21284351 | Predicting Bevirimat resistance of HIV-1 from genotype |
| Q41844750 | Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process |
| Q36967857 | Recent progress in antiretrovirals--lessons from resistance |
| Q90646261 | Resistance to Second-Generation HIV-1 Maturation Inhibitors |
| Q28485054 | Structural and functional insights into the HIV-1 maturation inhibitor binding pocket |
| Q28828191 | Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 |
| Q37928913 | Targeting human immunodeficiency virus type 1 assembly, maturation and budding. |
| Q37979697 | Targets for inhibition of HIV replication: entry, enzyme action, release and maturation |
| Q30437103 | The structural biology of HIV assembly |
| Q39630669 | Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication |
| Q33356201 | Understanding HIV-1 protease autoprocessing for novel therapeutic development |
| Q33774977 | Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid |
| Q24642446 | Virus maturation as a new HIV-1 therapeutic target |
Search more.